Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

The promise of monoclonal antibody treatments for Alzheimer’s disease — Whalespan

Content›Video›The promise of monoclonal an…

The promise of monoclonal antibody treatments for Alzheimer’s disease

Peter Attia11m · 2021-06-08

Claims Made

19

Claims Supported

11

Support Rate

58%

Support rate

11 of 19 claims supported

11 supported8 partial / not

Claims from this content

10

✓Well SupportedAPOE4 carriers are given a lower dose of certain drugs due to the risk of amyloid-related imaging abnormalities (ARIA).◐Partially SupportedDrugs that remove amyloid plaques may have controversial and potentially insufficient or too late positive results on cognition.◐Partially SupportedIntervening when amyloid is detected before cognitive impairment develops is the ideal strategy for modifying Alzheimer's disease.◐Partially SupportedAnti-amyloid drugs reduce amyloid levels, demonstrated by patients transitioning from positive to negative amyloid PET scans.Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

◐

Anti-amyloid drugs may have an opportunity to work in patients with mild cognitive impairment.

◐Partially SupportedAducanumab is a monoclonal antibody for amyloid that reached Phase 3 trials.

◐Partially SupportedThe highest dose in the study was approximately 10 milligrams per kilogram.

◐Partially SupportedThe drug donanemab met primary and secondary outcome measures in a study.

◐Partially SupportedAPOE4 carriers can receive the higher dose (10 mg/kg) of the drug.

◐Partially SupportedThe study stratified participants based on APOE status, giving a lower dose to APOE4 carriers and a higher dose to non-carriers.